

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 December 2021 (23.12.2021)



(10) International Publication Number
WO 2021/253095 A1

(51) International Patent Classification:

C07D 403/12 (2006.01) C07D 413/14 (2006.01)
C07D 231/38 (2006.01) C07D 417/12 (2006.01)
C07D 401/12 (2006.01) C07D 417/14 (2006.01)
C07D 401/14 (2006.01) C07D 487/04 (2006.01)
C07D 407/14 (2006.01) C07D 498/04 (2006.01)
C07D 413/12 (2006.01) A61P 43/00 (2006.01)

(21) International Application Number:

PCT/AU2021/050638

(22) International Filing Date:

18 June 2021 (18.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2020902035 19 June 2020 (19.06.2020) AU

(71) Applicant: **ANAXIS PHARMA PTY LTD** [AU/AU]; 1G
Royal Parade, Parkville, Victoria 3052 (AU).

(72) Inventors: **GARNIER, Jean-Marc Daniel**; c/- 1G Royal
Parade, Parkville, Victoria 3052 (AU). **BRZOWSKI,
Martin**; c/- 1G Royal Parade, Parkville, Victoria 3052
(AU). **FEUTRILL, John Thomas**; c/- 1G Royal Parade,
Parkville, Victoria 3052 (AU). **LESSENE, Guillaume
Laurent**; c/- 1G Royal Parade, Parkville, Victoria 3052
(AU). **GARDNER, Christopher**; c/- 1G Royal Parade,
Parkville, Victoria 3052 (AU). **CZABOTAR, Peter Ed-
ward**; c/- 1G Royal Parade, Parkville, Victoria 3052 (AU).
COWAN, Angus; c/- 1G Royal Parade, Parkville, Victo-
ria 3052 (AU). **DAVIES, Katherine**; c/- 1G Royal Parade,
Parkville, Victoria 3052 (AU). **SHARMA, Pooja**; c/- 1G
Royal Parade, Parkville, Victoria 3052 (AU). **SCHUSTER-
KLEIN, Carole Annie**; c/- 1G Royal Parade, Parkville,
Victoria 3052 (AU). **POITEVIN, Christophe**; c/- 1G Roy-
al Parade, Parkville, Victoria 3052 (AU).

(74) Agent: **FPA PATENT ATTORNEYS PTY LTD**; Level
43, 101 Collins Street, Melbourne, Victoria 3000 (AU).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,


CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: SULPHONAMIDE COMPOUNDS



(57) Abstract: This invention relates to compounds of formula (I) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (I) to treat necroptosis and/or inhibit MLKL.